Maximilian Papi

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 289 citations · Full text

Staging of Breast Cancer: New Recommended Standard Procedure

Alberto Ravaioli, A. Polselli, Maximilian Papi et al. · Breast Cancer Research and Treatment · 2002 · 98 citations

Surgical Oncology, Breast Oncology, Medicine +6

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

Paola Ulivi, Elisa Chiadini, Claudio Dazzi et al. · Clinical Lung Cancer · 2015 · 89 citations

Clinical-pathological Characteristics, Medicine, Pathology +6

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Journal of Clinical Medicine · 2020 · 68 citations · Full text

A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

Federico Cappuzzo, Silvia Novello, Filippo de Marinis et al. · Lung Cancer · 2006 · 38 citations

Oncology, Medicine, Clinical Trials +8